ArticleInternational journal of nanomedicine2026
Transferrin-Functionalized Conjugated Polymer Nanoparticles for Enhanced Photodynamic Therapy of Glioblastoma.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Glioblastoma (GBM) remains one of the most lethal primary brain tumors due to its highly infiltrative nature, pronounced intratumoral heterogeneity, and the restrictive blood-brain barrier (BBB), which severely limit the efficacy of conventional therapies. Photodynamic therapy (PDT) offers a spatially and temporally controllable treatment modality; however, its clinical translation for GBM is hindered by insufficient tumor selectivity and suboptimal photosensitizer delivery to intracranial lesions. The purpose of this study was to develop and preclinically evaluate transferrin-functionalized conjugated polymer nanoparticles (CPNs) as a receptor-targeted nanoplatform to enhance BBB traversal, tumor cell uptake, and photodynamic therapeutic efficacy in GBM. Methods: F8BT-based CPNs doped with platinum(II) octaethylporphyrin (PtOEP) and stabilized with poly(styrene-co-maleic anhydride) (PSMA) were synthesized by controlled nanoprecipitation and covalently conjugated to holo-transferrin (holo-Tf) using EDC/NHS chemistry. Nanoparticles were characterized by dynamic light scattering, zeta potential, UV-visible and fluorescence spectroscopy, transmission electron microscopy, electrophoretic mobility, and protein quantification assays. Cellular uptake, receptor specificity, and photodynamic cytotoxicity were evaluated in GBM cell lines. Therapeutic efficacy was further assessed in an orthotopic U87MG-tdiRFP glioblastoma mouse model. Results: Holo-Tf functionalization increased nanoparticle hydrodynamic diameter, reduced surface charge magnitude, and introduced a protein-specific absorbance feature, while preserving colloidal stability and optical properties. Protein quantification assays confirmed retention of more than 70% of the input holo-Tf. In vitro, holo-Tf CPNs showed significantly enhanced uptake in TfR-high U87MG cells compared with non-functionalized CPNs (42% vs 18% nanoparticle-positive cells at 1 h; gMFI 211 vs 73 at 4 h), which was reduced by excess free holo-Tf, indicating receptor-mediated uptake. PDT mediated by holo-Tf CPNs produced greater phototoxicity in vitro and, in vivo, reduced tumor fluorescence and prolonged survival relative to controls. Conclusion: Transferrin functionalization enhances receptor-directed delivery and PDT efficacy of conjugated polymer nanoparticles in GBM, supporting their further optimization and translational development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.